Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
16-30 of 4358 results
Zynerba halts development of THC prodrug ZYN001
By PBR Staff Writer
A failure in a phase 1 clinical program has forced Zynerba Pharmaceuticals to stop development of ZYN001, its pro-drug of tetrahydrocannabinol (THC) intended for the treatment of neuropsychiatric disorders including Tourette Syndrome.
Contract Research & Services > Clinical Trials > News
Anavex gets approval to begin phase 2b/3 trial of Alzheimer’s disease treatment
By PBR Staff Writer
Anavex Life Sciences has secured approval from the Australian Human Research Ethics Committee to begin its phase 2b/3 trial of Anavex 2-73 to treat early Alzheimer’s disease.
Contract Research & Services > Clinical Trials > News
Roche’s Tecentriq plus chemo meets PFS goal in triple negative breast cancer
By PBR Staff Writer
Roche said that a phase 3 study evaluating the Tecentriq (atezolizumab) and chemotherapy combination as a first-line treatment for triple negative breast cancer met its co-primary endpoint of progression-free survival (PFS).
Contract Research & Services > Clinical Trials > News
Arsanis to discontinue phase 2 trial of pneumonia drug over futility
Arsanis said that it will discontinue its phase 2 clinical trial of ASN100 for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients following the completion of a planned interim analysis of unblinded trial data by an independent data review committee (DRC).
Contract Research & Services > Clinical Trials > News
Lynparza delays disease progression in phase III trial for ovarian cancer
AstraZeneca and Merck have announced positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets.
Contract Research & Services > Clinical Trials > News
Pfizer’s Ibrance breast cancer drug combo fails to improve OS in phase 3 trial
By PBR Staff Writer
Pfizer said that its breast cancer drug Ibrance (palbociclib) in combination with fulvestrant was not statistical significant in extending overall survival (OS) in a phase 3 Paloma-3 trial.
Contract Research & Services > Clinical Trials > News
Arcus, Infinity to evaluate two triple combination therapies in selected tumor types
Arcus Biosciences and Infinity Pharmaceuticals have entered into a clinical collaboration to evaluate two triple combination therapies in certain tumor types which typically show minimal response to checkpoint inhibition monotherapy.
Contract Research & Services > Clinical Trials > News
Synairgen reports positive safety data for SNG001 in phase 2 COPD trial
By PBR Staff Writer
Synairgen said that its antiviral therapy SNG001 has so far registered positive safety data in an ongoing phase 2 trial in patients with chronic obstructive pulmonary disease (COPD).
Contract Research & Services > Clinical Trials > News
New drug cuts hearing loss in children by 50% after cancer treatment
By PBR Staff Writer
A clinical trial, funded by Cancer Research UK, has shown that administering sodium thiosulphate (STS) after chemotherapy ‘cisplatin’ for the treatment of childhood liver cancer hepatoblastoma reduces hearing loss in children by almost 50%.
Contract Research & Services > Clinical Trials > News
Novo Nordisk’s semaglutide succeeds in two phase 3a type 2 diabetes trials
By PBR Staff Writer
Novo Nordisk said that oral semaglutide succeeded in two phase 3a trials by registering statistically significantly greater reductions in HbA1c and weight in adults with type 2 diabetes.
Contract Research & Services > Clinical Trials > News
Can-Fite delays phase 2 trial of liver cancer drug Namodenoson
By PBR Staff Writer
Israeli biotechnology company Can-Fite BioPharma revealed that the results of its phase 2 trial of its liver cancer drug Namodenoson (CF102) will be delayed longer than originally estimated.
Contract Research & Services > Clinical Trials > News
X4P-001-RD demonstrates promising activity in WHIM syndrome patients
By PBR Staff Writer
X4 Pharmaceuticals said that its X4P-001-RD has demonstrated promising activity in the ongoing open-label phase 2 portion of a phase 2/3 study in patients with WHIM syndrome.
Contract Research & Services > Clinical Trials > News
BMS’ elotuzumab / pomalidomide improves progression-free survival in cancer trial
Bristol-Myers Squibb (BMS) has announced that the ELOQUENT-3 trial, an international Phase 2 study evaluating the addition of Empliciti (elotuzumab) to pomalidomide and low-dose dexamethasone (EPd) in patients with relapsed/refractory multiple myeloma (RRMM), achieved its primary endpoint.
Contract Research & Services > Clinical Trials > News
Futility forces Teva to halt fremanezumab’s chronic cluster headache study
By PBR Staff Writer
Israel-based Teva Pharmaceutical Industries said that it will stop an ongoing phase 3 trial of its migraine drug fremanezumab for the treatment of chronic cluster headache due to futility.
Contract Research & Services > Clinical Trials > News
Faron Pharmaceuticals reports inconsistent Traumakine biomarker results
Faron Pharmaceuticals has announced preliminary biomarker data from its Phase III INTEREST trial of Traumakine for the treatment of Acute Respiratory Distress Syndrome (ARDS).
Contract Research & Services > Clinical Trials > News
16-30 of 4358 results